To investigate the role of plasmin(ogen) in mammary tumor development and progression, plasminogende®cient mice were crossed with transgenic mice expressing Polyoma middle T antigen under the control of the mouse mammary tumor virus long terminal repeat. Virgin females carrying the Polyoma middle T antigen uniformly developed multiple, bilateral mammary tumors, regardless of the presence or absence of circulating plasminogen. Both the age at which these tumors became palpable and subsequent tumor growth were indistinguishable between plasminogen-de®cient mice and plasminogen-expressing littermates. However, plasminogen was found to greatly modify the metastatic potential in this model system; lung metastasis in plasminogende®cient mice was signi®cantly reduced as compared to littermate controls with respect to frequency of occurrence, total number of metastases, and total metastatic tumor burden. Plasminogen activators, as well as other key factors that govern the conversion of plasminogen to plasmin, were expressed within the mammary tumors, suggesting that the plasminogen/plasmin system may promote metastasis by contributing to tumor-associated extracellular proteolysis. The data provide direct evidence that plasmin(ogen) is a tumor progression factor in PymT-induced mammary cancer, and support the hypothesis that hemostatic factors play an important role in tumor biology.
Introduction
Plasminogen activation is governed by a sophisticated system of extracellular serine proteases, protease receptors, and protease inhibitors that both regulate and spatially focus the conversion of plasminogen (Plg) to the active protease, plasmin (Danù et al., 1985 Saksela and Rifkin, 1988; Vassali et al., 1991 Vassali et al., , 1992 . Plasmin eciently degrades ®brin and has a well-established role in thrombolysis (Collen and Lijnen, 1994) . Plasmin also has a critical physiological role in the degradation of ®brin-rich extracellular matrices in the context of tissue repair and homeostasis (Bugge et al., 1995 Ploplis et al., 1995; Rùmer et al., 1996; Schuster et al., 1997; Xiao et al., 1997; Drew et al., 1998) . Plasmin(ogen) has also been shown to have a critical role in bacterial invasion (Coleman et al., 1997) , and pathologic neuronal degeneration (Tsirka et al., 1997a) . In addition, plasmin-mediated proteolysis has been proposed to contribute to the progression of many degenerative diseases including, rheumatoid arthritis (Werb et al., 1977; Mochan and Uhl, 1984) , chronic corneal ulceration (Salonen et al., 1987) , psoriasis (Fraki et al., 1983) , and cancer.
The evidence that plasmin participates in matrix proteolysis associated with tumor development, invasion, and metastasis is impressive, but largely indirect. Most malignant tumors express various components of the plasminogen activation system at areas of active invasion, implying an important role in extracellular matrix degradation (Skriver et al., 1984; Pyke et al., 1991a Pyke et al., ,b, 1993 . Furthermore, multiple clinical studies have demonstrated an association between high levels of expression of plasminogen activator (PA), PA inhibitor, or PA receptor and poor clinical outcome in human breast, colorectal, lung, and other types of cancer (Sappino et al., 1987; Heinert et al., 1988; Janicke et al., 1989; Duy et al., 1990; Oka et al., 1991; Foekens et al., 1992; Grùndahl-Hansen et al., 1993; Ganesh et al., 1994; Mulcahy et al., 1994; Nekarda et al., 1994; Pedersen et al., 1994; Heiss et al., 1995) . In several experimental tumor models, the invasion or metastasis of malignant tumors transplanted to animals was impaired by PA inhibitors including antisense RNA, anti-catalytic PA antibodies, natural and synthetic PA-inhibitors, and PA receptor antagonists (Ossowski and Reich, 1983; Hearing et al., 1988; Ossowski 1988; Yu et al., 1990; Ossowski et al., 1991; Crowley et al., 1993; Kobayashi et al., 1994a, b; Kook et al., 1994; Mueller et al., 1995; Rabbani et al., 1995; Min et al., 1996) . Moreover, in a recent study Rifkin and colleagues showed that the progression of 7,12-dimethylbenz(a)anthracene and croton oil-induced primary cutaneous melanocytic neoplasia was delayed in urokinase-type plasminogen activator-de®cient mice .
Plasminogen-de®cient (Plg
) mice are viable and fertile, and are generally healthy during young adulthood, although a variety of phenotypic abnormalities develop as the mice age that appear to be speci®cally associated with impaired ®brinolysis (Bugge et al., 1995 Ploplis et al., 1995) . The availability of viable and fertile Plg 7/7 mice provides a unique new opportunity to directly de®ne the role of plasminmediated proteolysis in tumor progression in vivo. In this paper, we have used an established animal model for malignant mammary cancer, transgenic mice expressing Polyoma virus middle T antigen (PymT) under the control of the mouse mammary tumor virus long terminal repeat (Guy et al., 1992) , to de®ne the impact of Plg-de®ciency on mammary tumor development and metastasis. We report that the absence of Plg does not appreciably alter primary tumor development, but does signi®cantly reduce the metastatic potential.
Results

Polyomavirus middle T-induced mammary tumors express plasminogen activator and inhibitor
To examine the impact of Plg de®ciency on mammary tumor biology, plasminogen-de®cient (Plg 7/7 ) mice (Bugge et al., 1995) were crossed to transgenic mice predisposed to malignant mammary adenocarcinoma as a result of mammary gland-directed expression of a PymT oncogene (Guy et al., 1992 /PymT + mice for the presence of key plasminogen activator system components showed that tissue-type plasminogen activator (tPA) and urokinase (uPA) were uniformly and easily detected by zymography (data not shown). uPA receptor was also expressed in tumor tissue based on Northern blot analysis of tumor-derived RNA (data not shown). In situ hybidization studies using mammary tumor sections from both Plg /PymT + mice showed pronounced local expression of mRNA encoding both uPA and its primary inhibitor, plasminogen activator inhibitor-1 (PAI-1) (data not shown). uPA expression was primarily localized to tumor-associated stromal cells, analogous to the human ductal adenocarcinoma (Nielsen et al., 1996) . uPA mRNA was particularly abundant in scattered stromal cells within the outer tumor margins, adjacent to areas containing appreciable ®brin-rich extracellular matrix, and within the inner tumor margins, adjacent to central necrotic regions. Most PAI-1 positive cells were found immediately surrounding nests of invasive tumor cells in the tumor periphery, but positive cells were also seen centrally.
Primary mammary tumor development in Plg 7/7 mice To rigorously determine the impact of total Plg de®ciency on primary mammary tumor development, we followed a prospective cohort consisting of 31 female Plg Figure 1a ). To quantitate primary tumor development in greater detail, mammary tissues were removed from mice 96 ± 100 days of age, and the number of mammary glands with solid tumor nodules, as well as the total mammary tumor burden were determined (Figure 1b and c , 31.0+5.1). Taken together, the data suggest that the impact of Plg de®ciency on the general health of the mice is also not a major confounding issue in the study of tumor development in these young mice.
Histological characterization of primary mammary tumors
To further characterize mammary tumor development in the absence of Plg, we performed a histological characterization of primary tumors from 69 days, 96 to 100 days, and 138 to 139-days-old P (Bugge et al., 1995; Ploplis et al., 1995) and Plg-de®cient humans (Schuster et al., 1997) , no obvious dierences were observed in the extent of ®brin(ogen) deposition between tumors from control and Plg 7 / 7 mice. However, it should be noted that the immunohistochemical analyses of ®brin(ogen) deposition within tumors were qualitative in nature, and incremental dierences in ®brin within or around tumors of P 7 T + and P + T + mice may be revealed in quantitative studies.
Histological characterization of lung metastasis
Tumor foci were frequently detected by microscopic analysis of lung tissue from P 7 T + and P + T + mice (Figure 3 ). These foci could be unequivocally identi®ed as metastatic mammary carcinoma by their strong expression of mRNA for the mammary epithelial cellspeci®c secretory protein b-casein as detected by in situ hybridization (Figure 4) or by Northern blot analysis of total RNA from lungs of P 7 T + and P + T + , but not from T 7 mice (data not shown). However, given that b-casein expression varied considerably within tumor nodules (see Figure 4) , the level of b-casein mRNA in total RNA extracts from mammary glands could not be used as a reliable measure of metastatic tumor burden. Nevertheless, the majority, if not all, of the tumors observed in the lung appeared to be mammary tumor-derived metastases; over 80% of tumor nodules randomly evaluated in P + T + mice (23 of 27 metastases examined in three lung sections from three animals) and P 7 T + mice (8 of 10 metastases examined in three sections from three animals) exhibited at least some bcasein expression based on in situ hybridization.
Apart from the reduced frequency, a detailed microscopic examination of lung sections of 96 to 100-days-old and 135 to 139-days-old P + T + mice and P 7 T + mice did not reveal any obvious histological dierences between metastatic foci developing in the presence and absence of Plg (Figure 3 and data not shown). Interestingly, no appreciable ®brin was evident within the malignant pulmonary tumor masses of either P 7 T + or P + T + mice, as assessed by immunohistochemistry using ®brin(ogen) antibodies (Figure 3) . Rather, ®brin(ogen) was speci®cally detected within the immediately adjacent lung tissue ( Figure 3 ).
Reduced lung metastasis in Plg-de®cient mice
To determine the impact of loss of Plg on the metastatic potential of PymT-induced mammary tumors, metastasis was quantitated by microscopic analysis of lung sections prepared from P 7 T + and P + T + (data summary shown in Table 1 ). By this method of quantitation, no metastatic foci were detected in 69-day-old mice of any genotype (data not shown). In 96 to 100-days-old mice, lung metastasis was detected in 18/41 (44%) of the mice analysed. However, metastasis was detected significantly less frequently in P 7 T + mice [4/16 (25%)] relative to P + T + mice [14/25 (56%)], (P50.04). The occurrence of metastasis was strongly correlated with a high primary tumor burden. Thus, among the 21 mice analysed that had primary tumor burdens below the median value of 4 g, only three (14%) had detectable lung metastases (all P + T + mice). In contrast, 15/20 (75%) of the mice analysed which had primary tumor burdens above the median value of 4 g presented with metastasis (P50.0001, Chi-square analysis). In mice with a primary tumor burden above 4 g, 11/11 (100%) of the P + T + mice (median primary tumor burden 7.5 g; range 4.1 ± 16.1 g) demonstrated metastasis, as compared to 4/9 (44%) of the P 7 T + mice (median primary tumor burden 6.6 g; range 4.3 ± 11.7 g) (P50.005). Furthermore, in the group of mice with a primary tumor burden above 4 g, both the total number of metastases as well as the total area of lung sections To study the impact of plasminogen de®ciency on later stages of tumor dissemination, we quantitated metastasis in a small number of P 
Discussion
The data presented in this paper indicate that Plg contributes to the metastatic dissemination of PymT oncogene-induced mammary cancer. Primary mammary tumors in Plg 7/7 mice developed normally with respect to the time of appearance and rate of growth, but were signi®cantly less metastatic. A trivial explanation for our ®ndings could be that the diminished rate of dissemination of mammary tumors in Plg 7/7 mice is a simple consequence of a general impairment of health associated with Plg de®ciency. However, this is improbable for two reasons. First, the Plg 7/7 mice in this genetic background did not display signs of failing health within the observation period, as evidenced by appearance, behavior, and weight gain. Second, the rate of growth of the primary mammary tumors was unaected by Plg de®ciency, and it seems unlikely that a general failure of health would in¯uence metastasis, but not primary tumor growth. Therefore, it appears that one or more speci®c plasmin(ogen)-mediated processes increase the metastatic potential of malignant mammary tumors.
Cancer invasion and metastasis is a complex process that involves multiple discrete steps, such as vasation, arrest, extravasation, growth, and development of a supporting neovasculature. The data in this paper do not identify the step(s) in the metastatic pathway that are aected by the lack of Plg, since only the end- result, i.e., the formation of metastatic foci, was quantitated. Lack of plasmin-mediated proteolysis could theoretically aect any of the aforementioned steps. It is also conceivable that Plg de®ciency may impair some of the steps of tumor dissemination, while accelerating others, with reduced metastasis being the net result. Additional, more detailed studies of tumor biology in Plg 7/7 mice will be necessary to clarify these issues.
Degradation of ®brin-rich extracellular matrices appears to be the principle physiological role of plasmin . However, impaired ®brin clearance is not necessarily the key impediment to tumor dissemination in the Plg 7/7 mice. It is clear that in at least some pathological settings plasmin cleaves substrate(s) that are dierent from ®brin (Tsirka et al., 1997b) , and virtually all the biochemical functions previously ascribed to plasmin (e.g., activation of tumor-associated growth factors and matrix metalloproteases, general matrix and basement membrane degradation, and ®brinolysis (Werb et al., 1977; Brunner et al., 1991; Vasalli et al., 1991;  Control Plg Odekon et al., 1994) could potentially accelerate tumor progression, either alone or in combination. We demonstrated that ®brin(ogen) is a component of the tumor stroma of PymT-induced mammary tumors, as it is in most human and experimental tumors. Fibrin-rich matrices have been proposed to provide a supportive or stabilizing matrix for growth and organization of the tumor stroma and malignant cells, analogous to the role of ®brin in wound healing (Harris et al., 1982; Dvorak 1986; Brown et al., 1988; Dvorak et al., 1992; Nagy et al., 1995a,b) . However, in the absence of plasmin-mediated fibrinolysis, ®brin may constitute a signi®cant physical barrier, slowing, but not preventing, tumor dissemination. Tumor studies in Plg and ®brinogen doublede®cient PymT + mice are in progress to directly test this hypothesis.
We recently found that Plg de®ciency has a dierent eect on another highly metastatic tumor, the Lewis lung carcinoma. Lewis lung carcinoma transplanted into the subcutis of histocompatible Plg 7/7 mice displayed substantially reduced growth at the site of injection and reduced regional lymph node metastasis, whereas no quantitative changes could be detected in lung metastasis . Thus, the importance of Plg for tumor development, invasion and metastasis may vary in individual tumor types. The site of primary tumor development, as well as the overall pattern of expression of matrix-degrading proteases, protease receptors and inhibitors, procoagulants, growth factors, extracellular matrix components, adhesion molecules, and matrix proteins by the tumor and stromal cells may determine the relative importance of Plg in tumor progression. A systematic determination of the behavior of multiple distinct classes of human and experimental tumors in control and Plg 7/7 mice, including adenomas, carcinomas, ascites tumors, and leukemias, will be necessary to de®ne the general importance of Plg in tumor biology.
The data presented in this paper demonstrate that one or more processes critical to mammary tumor dissemination is signi®cantly inhibited by the lack of Plg. Beside the Plg system, a number of serine, metallo, aspartic and cysteine proteases have been implicated in tumor invasion and metastasis (Danù et al., 1985; Duy 1992; Stetler-Stevenson et al., 1993; Crawford and Matrisian, 1995; Kohn and Liotta, 1995; Schwartz, 1995; Liotta and Steeg, 1991) . The recent development of speci®c and ecient synthetic inhibitors of matrixdegrading proteases, as well as several transgenic mouse lines de®cient in matrix-degrading proteases or overexpressing protease inhibitors, has provided powerful tools to directly dissect the individual roles of matrix-degrading proteases in cancer invasion and metastasis in vivo (Bugge et al., 1995; Ploplis et al., 1995; Anderson et al., 1996; Carmeliet et al., 1994; Saftig et al., 1995; Wilson et al., 1997; Conway et al., 1996; Sledge et al., 1995; Shipley et al., 1996; Martin et al., 1996) . Studies of the eect of the combined elimination of several tumor-associated matrix-degrading enzymes using available inhibitors and genede®cient mice will be critical for evaluating the potential for the development of ecient cancer treatments based on the inhibition of matrix-degrading proteases.
Materials and methods
Generation of mice and genotype analysis
Plg gene-targeted female mice of a mixed 129/Black Swiss background (Bugge et al., 1995) were crossed to male mice transgenic for the MMTV-PymT oncogene in an inbred FvB/N background (PymT line #634; Guy et al., 1992) . Plg +/7 /PymT + males from the ensuing ospring were mated to 129/Black Swiss Plg +/7 females, to generate Plg +/+ /PymT + , Plg +/7 /PymT + and Plg 7/7 /PymT + mice for experiments. All mice used for experiments were female virgins. All experimental evaluations were performed by an investigator unaware of animal genotype. Genotyping of the Plg alleles was performed as described . The presence of the MMTV-PymT transgene was detected by PCR using the primers 5'-CGGCGGAGC-GAGGAACTGAGGAGAG-3' and 5'-TCAGAAGACTC-GGCAGTCTTAGGCG-3', corresponding to positions 811 ± 835 and 970 ± 945, respectively, in the published sequence of the Polyoma virus (Soeda et al., 1980) , that yield a 160 bp product.
Histological analysis
Mice were sacri®ced under ketamine anesthesia as described previously , and the mice were perfused with cold phosphate buered saline (PBS). The mammary tumors and lungs were excised and ®xed for 24 h in 4% (w/v) paraformaldehyde in PBS or 10% neutral buered formalin. Fixed tissues were processed into paran, sectioned, and stained either with hematoxylin/ eosin or Masson's trichrome.
Immunohistochemistry
Five mm tissue sections were deparanized in xylene, hydrated in graded ethanol solutions and blocked for endogenous peroxidase in 1% hydrogen peroxide for 15 min. Sections were trypsinized for 5 ± 10 min with 0.025 mg/ml trypsin (Sigma T8128) in a 0.5 M Tris buer containing 0.1% CaCl 2 . Sections were washed in Tris buered saline containing 0.5% Triton X-100 (TBS-T) for 10 min before incubation with primary antibodies. The rabbit polyclonal antibody to mouse ®brin(ogen) (HolmbaÈ ck et al., 1996) was diluted 1 : 1000 in TBS containing 0.25% bovine serum albumin (BSA), incubated overnight at 48C, and detected with biotinylated swine anti-rabbit secondary antibody (DAKO E353), followed by streptavidin/horseradish-peroxidase complexes (DAKO K377). The sections were washed for 15 min in TBS-T between each incubation and developed either with 3,3'-diaminobenzidine tetrahydrochloride (Sigma), or 0.25 mg/ml 3-amino-9-ethyl carbazole (AEC, Sigma, A5754) in 0.05 M acetic acid, pH 5.0 for 5 ± 10 min. Non-immune rabbit IgG diluted 1 : 1000 was used as negative control.
In situ hybridization
In situ hybridization was performed essentially as described (Rùmer et al., 1991) . Brie¯y, 5 mm paran sections were deparanized and rehydrated as described above, and proteinase-K digested with 5 mg/ml in 50 mM Tris-HCl, pH 8.0 containing 5 mM EDTA for 4 min at 448C. Probes were incubated overnight at 478C using 2610 6 cpm probe per section. Sections were washed at 538C in 26SSC containing 10 mM dithiothreitol (DTT) and 0.01% sodium dodecyl sulfate (SDS) for 1 h, and 0.56SSC containing 10 mM DTT and 0.01% SDS for 1 h. Sections were developed for 7 days. For detection of uPA mRNA, a 1034 bp EcoRI-nPstI fragment (position 608 to 1642 of the mouse uPA gene in Belin et al., 1985) from the plasmid pmuPA-07 (Rùmer et al., 1991) was used. For detection of PAI-1 mRNA, a 519 bp PstI-XhoI fragment (position 338 to 857 of the mouse PAI-1 cDNA in Prendergast et al., 1990 ) from the plasmid pmPAI1-03 was used (Rùmer et al., 1991) . For detection of b-casein mRNA. a 540 bp PstI fragment from the plasmid pBCL-1 (M Bissel. unpublished) was used.
Quantitation of lung metastasis
Fixed lung tissue was prepared as described above. Three parallel sections separated by 150 mm were prepared from each pair of lungs and stained with hematoxylin/eosin, or Masson's trichrome. The sections were randomized and coded, the total number of metastatic foci were counted, and the area of each metastatic focus and the total lung surface area was measured with a graticule.
Northern blot analysis
Total RNA was isolated from primary tumors and lungs of the mice as described previously (HolmbaÈ ck et al., 1996) . Samples of RNA (10 mg for b-casein mRNA analysis, and 20 mg for urokinase plasminogen activator receptor (uPAR) mRNA analysis) were electrophoretically-fractionated on denaturing agarose gels, transferred to BA85 nitrocellulose ®lters, and hybridized with a 32 P-labeled 540 bp DNA fragment from the mouse b-casein cDNA (kindly provided by M Bissel), or a 32 P-labeled 1500 bp mouse uPAR cDNA probe .
Casein-Plg zymography of tumor extracts
Mice were perfused with cold PBS under ketamine anesthesia as described previously . Mammary tumors were excised and immediately frozen in liquid N 2 . The tissue was pulverized and suspended in 5 volumes of extraction buer (0.5 M Tris-HCl, pH 7.6, 1% Triton X-100, 200 mM NaCl and 10 mM CaCl 2 ). The suspension was freeze-thawed four times, and clari®ed by centrifugation at 12 000 g for 30 min. uPA and tPA activities of 1 ml fractions were detected by casein-Plg zymography as described previously (Bugge et al., 1995) , after developing the zymograms for 20 h.
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